CCM
SPRY icon

CAAS Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

CAAS Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-25,000
Closed -$1.09M – 1264
2021
Q1 		$1.09M Hold
25,000
– – 0.01% 750
2020
Q4 		$1.16M Buy
+25,000
New +$835K 0.01% 582

Other funds holding SPRY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

CAAS Capital Management's SPRY Position: Q2 2021 in Review

CAAS Capital Management sold out of ARS Pharmaceuticals (SPRY) in Q2 2021, closing a stake of 25,000 shares — an estimated $1.09M sold.

CAAS Capital Management first reported a position in SPRY in Q4 2020 and held it in 2 quarters. The position peaked at $1.16M in Q4 2020. 76 funds tracked by Wall St. Rank hold SPRY as of Q2 2021.

  • CAAS Capital Management reported no remaining ARS Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 25,000 ARS Pharmaceuticals shares in Q2 2021, an estimated $1.09M.
  • CAAS Capital Management first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • CAAS Capital Management's ARS Pharmaceuticals position peaked at $1.16M in Q4 2020.
  • 76 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.